Targeted therapies in the treatment of advanced hepatocellular carcinoma.

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int (2015) 1.59

Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumour Biol (2013) 1.08

Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy. Cell Mol Gastroenterol Hepatol (2015) 0.86

Nonalcoholic Lipid Accumulation and Hepatocyte Malignant Transformation. J Clin Transl Hepatol (2016) 0.76

Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99

The biology of VEGF and its receptors. Nat Med (2003) 32.13

The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11

Management of hepatocellular carcinoma. Hepatology (2005) 27.42

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36

mTOR and cancer: insights into a complex relationship. Nat Rev Cancer (2006) 11.86

Primary liver cancer: worldwide incidence and trends. Gastroenterology (2004) 11.21

WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet (2004) 10.38

Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell (1993) 10.36

Role of insulin-like growth factors in embryonic and postnatal growth. Cell (1993) 8.22

Liver regeneration. Hepatology (2006) 7.52

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol (2005) 7.12

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95

Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res (2006) 6.66

Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16

Epidermal growth factor receptor (EGFR) signaling in cancer. Gene (2005) 6.04

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology (2004) 5.83

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol (2004) 5.12

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA (2010) 4.71

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54

Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov (2007) 4.27

Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95

Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol (2005) 3.62

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets (2008) 3.36

Non-oncogene addiction and the stress phenotype of cancer cells. Cell (2007) 3.19

Hepatocellular carcinoma and hepatitis C in the United States. Hepatology (2002) 3.00

DNA methylation and chromatin - unraveling the tangled web. Oncogene (2002) 2.79

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res (2005) 2.76

The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res (2008) 2.70

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol (2009) 2.69

The IGF-1 receptor in cancer biology. Int J Cancer (2003) 2.66

Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int (2008) 2.65

Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res (2006) 2.65

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol (2005) 2.56

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol (2009) 2.53

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 2.38

Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther (2009) 2.31

Angiogenesis and hepatocellular carcinoma. J Hepatol (2004) 2.25

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther (2010) 2.18

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res (2009) 2.08

The epidermal growth factor receptor: from development to tumorigenesis. Differentiation (2007) 2.07

Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther (2007) 2.01

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther (2008) 1.90

Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2011) 1.89

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer (2007) 1.83

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol (2005) 1.81

DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene (2011) 1.76

Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem (2009) 1.75

Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol (2002) 1.75

Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology (2012) 1.71

Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog (2012) 1.71

Chromatin remodeling, histone modifications, and DNA methylation-how does it all fit together? J Cell Biochem (2002) 1.67

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66

SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal (2010) 1.63

Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg (2004) 1.62

c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology (2011) 1.61

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer (2011) 1.59

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res (2008) 1.57

Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol (2007) 1.56

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer (2007) 1.56

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget (2012) 1.55

Targeting EGFR in colorectal cancer. N Engl J Med (2008) 1.52

Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos (2005) 1.48

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol (2009) 1.47

Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev (2005) 1.46

Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol (2003) 1.45

The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem (2009) 1.44

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res (2005) 1.36

Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res (2010) 1.36

An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl (2009) 1.31

Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology (2012) 1.30

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2012) 1.27

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A (2010) 1.26

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer (2010) 1.22

Targeted therapy of hepatocellular carcinoma: present and future. J Gastroenterol Hepatol (2012) 1.21

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med (2008) 1.19

miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. PLoS One (2013) 1.17

Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol (2012) 1.17

The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin Res Hepatol Gastroenterol (2011) 1.16

Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist (2011) 1.15

Is cell size important? Cell Cycle (2007) 1.12

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs (2006) 1.12

Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci (2007) 1.08

Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. World J Gastroenterol (2012) 1.05

Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study. J Hepatol (2012) 1.05

A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res (2009) 1.04

Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology (2012) 1.04

Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells. J Biol Chem (2011) 1.03

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol (2012) 4.58

High-speed graphene transistors with a self-aligned nanowire gate. Nature (2010) 3.48

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res (2009) 3.10

OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature (2007) 3.03

Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation (2010) 2.20

Algal genomes reveal evolutionary mosaicism and the fate of nucleomorphs. Nature (2012) 2.15

Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology (2011) 2.13

Cleavage specificity of Saccharomyces cerevisiae flap endonuclease 1 suggests a double-flap structure as the cellular substrate. J Biol Chem (2002) 2.06

Low prevalence of knee and back pain in southeast China; the Shantou COPCORD study. J Rheumatol (2004) 2.06

Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer (2012) 1.94

Biosynthesis of the salinosporamide A polyketide synthase substrate chloroethylmalonyl-coenzyme A from S-adenosyl-L-methionine. Proc Natl Acad Sci U S A (2009) 1.91

Proarrhythmic risk of embryonic stem cell-derived cardiomyocyte transplantation in infarcted myocardium. Heart Rhythm (2010) 1.89

Coordinated redistribution of leukocyte LFA-1 and endothelial cell ICAM-1 accompany neutrophil transmigration. J Exp Med (2004) 1.85

Highly efficient gate-tunable photocurrent generation in vertical heterostructures of layered materials. Nat Nanotechnol (2013) 1.72

Age-specific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in the California Teachers Study. Menopause (2011) 1.67

Genome-wide signatures of convergent evolution in echolocating mammals. Nature (2013) 1.59

Ten years' experience with needle biopsy in the early diagnosis of sacroiliitis. Arthritis Rheum (2012) 1.59

Chemical vapour deposition growth of large single crystals of monolayer and bilayer graphene. Nat Commun (2013) 1.57

Neutrophil migration across tight junctions is mediated by adhesive interactions between epithelial coxsackie and adenovirus receptor and a junctional adhesion molecule-like protein on neutrophils. Mol Biol Cell (2005) 1.57

BMP4-mediated brown fat-like changes in white adipose tissue alter glucose and energy homeostasis. Proc Natl Acad Sci U S A (2013) 1.55

Effects of cellulose crystallinity, hemicellulose, and lignin on the enzymatic hydrolysis of Miscanthus sinensis to monosaccharides. Biosci Biotechnol Biochem (2008) 1.54

HMGB1 is a cofactor in mammalian base excision repair. Mol Cell (2007) 1.49

Biosynthesis of the allylmalonyl-CoA extender unit for the FK506 polyketide synthase proceeds through a dedicated polyketide synthase and facilitates the mutasynthesis of analogues. J Am Chem Soc (2010) 1.49

Argonaute 2 complexes selectively protect the circulating microRNAs in cell-secreted microvesicles. PLoS One (2012) 1.47

Genome-wide association study identifies two new susceptibility loci for atopic dermatitis in the Chinese Han population. Nat Genet (2011) 1.46

Peregrine and saker falcon genome sequences provide insights into evolution of a predatory lifestyle. Nat Genet (2013) 1.45

Emergency medical rescue efforts after a major earthquake: lessons from the 2008 Wenchuan earthquake. Lancet (2012) 1.41

Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int J Cancer (2011) 1.39

A new technique for successful management of a complete suprahepatic caval transection. J Am Coll Surg (2007) 1.38

Flexible solid-state supercapacitors based on three-dimensional graphene hydrogel films. ACS Nano (2013) 1.38

CD44v4 is a major E-selectin ligand that mediates breast cancer cell transendothelial migration. PLoS One (2008) 1.36

Initiation of a critical pathway for pancreaticoduodenectomy at an academic institution--the first step in multidisciplinary team building. J Am Coll Surg (2007) 1.33

Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One (2011) 1.31

Tissue-autonomous function of Drosophila seipin in preventing ectopic lipid droplet formation. PLoS Genet (2011) 1.30

Scalar generalized nonlinear Schrödinger equation-quantified continuum generation in an all-normal dispersion photonic crystal fiber for broadband coherent optical sources. Opt Express (2010) 1.30

JAM-C is a component of desmosomes and a ligand for CD11b/CD18-mediated neutrophil transepithelial migration. Mol Biol Cell (2004) 1.29

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One (2013) 1.28

Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One (2011) 1.27

Thirteen Camellia chloroplast genome sequences determined by high-throughput sequencing: genome structure and phylogenetic relationships. BMC Evol Biol (2014) 1.24

Confirmation by exome sequencing of the pathogenic role of NCSTN mutations in acne inversa (hidradenitis suppurativa). J Invest Dermatol (2011) 1.23

Cloning and characterization of Disc1, the mouse ortholog of DISC1 (Disrupted-in-Schizophrenia 1). Genomics (2002) 1.22

PRPF4 mutations cause autosomal dominant retinitis pigmentosa. Hum Mol Genet (2014) 1.22

Graphene: an emerging electronic material. Adv Mater (2012) 1.21

Characteristics of particulate carbon emissions from real-world Chinese coal combustion. Environ Sci Technol (2008) 1.19

Mortality and morbidity associated with simultaneous bilateral or staged bilateral total knee arthroplasty: a meta-analysis. Arch Orthop Trauma Surg (2011) 1.19

Targeted sequencing of 179 genes associated with hereditary retinal dystrophies and 10 candidate genes identifies novel and known mutations in patients with various retinal diseases. Invest Ophthalmol Vis Sci (2013) 1.19

Survival After Sublobar Resection versus Lobectomy for Clinical Stage IA Lung Cancer: An Analysis from the National Cancer Data Base. J Thorac Oncol (2015) 1.18

Expression of voltage-gated potassium channels in human and rhesus pancreatic islets. Diabetes (2004) 1.16

Permanent Genetic Resources added to Molecular Ecology Resources Database 1 May 2009-31 July 2009. Mol Ecol Resour (2009) 1.15

MicroRNA-204 regulates vascular smooth muscle cell calcification in vitro and in vivo. Cardiovasc Res (2012) 1.14

CD11b/CD18-dependent interactions of neutrophils with intestinal epithelium are mediated by fucosylated proteoglycans. J Immunol (2002) 1.12

The DIADEM and beyond. Neuroinformatics (2011) 1.12

Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis. Nat Genet (2012) 1.12

Electroluminescence and photocurrent generation from atomically sharp WSe2/MoS2 heterojunction p-n diodes. Nano Lett (2014) 1.12

Role of miR-150-targeting c-Myb in colonic epithelial disruption during dextran sulphate sodium-induced murine experimental colitis and human ulcerative colitis. J Pathol (2011) 1.11

Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl (2010) 1.10

Runx2 integrates estrogen activity in osteoblasts. J Biol Chem (2003) 1.10

Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. J Virol (2010) 1.10

The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res (2013) 1.10

Association of BAP31 with CD11b/CD18. Potential role in intracellular trafficking of CD11b/CD18 in neutrophils. J Biol Chem (2004) 1.09

Intensity-modulated radiation therapy reduces radiation-induced trismus in patients with nasopharyngeal carcinoma: a prospective study with >5 years of follow-up. Cancer (2011) 1.09

Impact of obesity on perioperative morbidity and mortality after pancreaticoduodenectomy. J Am Coll Surg (2008) 1.08

Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res (2006) 1.08

Synergistic angiogenesis promoting effects of extracellular matrix scaffolds and adipose-derived stem cells during wound repair. Tissue Eng Part A (2010) 1.07

Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. Mol Cancer Ther (2011) 1.06

Characterization of adipocyte differentiation from human mesenchymal stem cells in bone marrow. BMC Dev Biol (2010) 1.06

Receptor for advanced glycation endproducts mediates neutrophil migration across intestinal epithelium. J Immunol (2007) 1.05

Autophagy inhibition through PI3K/Akt increases apoptosis by sodium selenite in NB4 cells. BMB Rep (2009) 1.05

Detection of hypervascular hepatocellular carcinoma: Comparison of multi-detector CT with digital subtraction angiography and Lipiodol CT. World J Gastroenterol (2005) 1.05

DNA polymerase beta-dependent long patch base excision repair in living cells. DNA Repair (Amst) (2009) 1.05

Anti-inflammatory and analgesic effect of plumbagin through inhibition of nuclear factor-κB activation. J Pharmacol Exp Ther (2010) 1.04

Regulation of gene expression by lithium and depletion of inositol in slices of adult rat cortex. Neuron (2005) 1.03

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs (2012) 1.03

Ultrasound-modulated fluorescence from rhodamine B aqueous solution. J Biomed Opt (2010) 1.03

MiR-133a modulates osteogenic differentiation of vascular smooth muscle cells. Endocrinology (2013) 1.02

High-resolution imaging in a deep turbid medium based on an ultrasound-switchable fluorescence technique. Appl Phys Lett (2012) 1.02

Role of microRNA-214-targeting phosphatase and tensin homolog in advanced glycation end product-induced apoptosis delay in monocytes. J Immunol (2011) 1.02

Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors. Bioorg Med Chem Lett (2011) 1.01

Prediction of total viable counts on chilled pork using an electronic nose combined with support vector machine. Meat Sci (2011) 1.01

MicroRNA-17/20a/106a modulate macrophage inflammatory responses through targeting signal-regulatory protein α. J Allergy Clin Immunol (2013) 1.01

Rapamycin sensitive mTOR activation mediates nerve growth factor (NGF) induced cell migration and pro-survival effects against hydrogen peroxide in retinal pigment epithelial cells. Biochem Biophys Res Commun (2011) 1.00

The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity. ChemMedChem (2011) 1.00

Nano-carrier for gene delivery and bioimaging based on carbon dots with PEI-passivation enhanced fluorescence. Biomaterials (2012) 1.00

The use of dentin matrix scaffold and dental follicle cells for dentin regeneration. Biomaterials (2009) 1.00

Gene set analysis in the cloud. Bioinformatics (2011) 1.00

Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice. Sci Transl Med (2013) 1.00

Cleavage of the CD11b extracellular domain by the leukocyte serprocidins is critical for neutrophil detachment during chemotaxis. Blood (2011) 0.99

Genotypic distribution of Candida albicans in dental biofilm of Chinese children associated with severe early childhood caries. Arch Oral Biol (2012) 0.99

Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent. Bioorg Med Chem (2012) 0.99

Model analysing the antioxidant responses of leaves and roots of switchgrass to NaCl-salinity stress. Plant Physiol Biochem (2012) 0.99

Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway. J Med Chem (2011) 0.99

Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation. J Cell Physiol (2012) 0.98

The immunopathology of liver granulomas in primary biliary cirrhosis. J Autoimmun (2012) 0.98

Attenuation of left ventricular adverse remodeling with epicardial patching after myocardial infarction. J Card Fail (2010) 0.97

Role of junctional adhesion molecule-like protein in mediating monocyte transendothelial migration. Arterioscler Thromb Vasc Biol (2008) 0.97

Gambogic acid induces G0/G1 arrest and apoptosis involving inhibition of SRC-3 and inactivation of Akt pathway in K562 leukemia cells. Toxicology (2009) 0.97

Enforced expression of METCAM/MUC18 increases tumorigenesis of human prostate cancer LNCaP cells in nude mice. J Urol (2011) 0.96

A meta-analysis of risk factors for depression in adults and children after natural disasters. BMC Public Health (2014) 0.96

Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients. Rheumatol Int (2012) 0.96

Transcriptome analysis and discovery of genes involved in immune pathways from hepatopancreas of microbial challenged mitten crab Eriocheir sinensis. PLoS One (2013) 0.96